Get the latest Venture Capital & Angel investors news and info Join Our Mailing List:

Your Name: 

Your Email:  

 
  • Ascenta Therapeutics Raises $50 Million in Series C Financing

    April 12th, 2007 No comments

    Ascenta Therapeutics, Inc. recently announced that it has raised $50 million in a Series C round of financing, with $30 million funded in a first tranche and the remainder to be funded upon the satisfaction of specific milestones. The round was led by two investment funds managed by Perseus, L.L.C., a buyout and growth equity investor with over $1.6 billion under management. Norman Selby, Senior Managing Director at Perseus, has joined the Ascenta Board of Directors. Upon full funding, the Series C financing will bring the total amount raised by the company to $85.5 million.

    All existing investors participated in this financing round, including Domain Associates, Sofinnova Ventures, Enterprise Partners Venture Capital, Scale Venture Partners (formerly BA Venture Partners), and US Venture Partners. Proceeds from the Series C financing will be used to advance AT-101, an oral pan-Bcl-2 inhibitor, through Phase 2 clinical trials in several cancers and to advance Ascenta’s pipeline programs to the clinic.

    “This new financing will permit Ascenta to accelerate and broaden the development of AT-101 in multiple cancer indications and advance our MDM2 and XIAP preclinical programs,” said Ascenta’s CEO, Mel Sorensen, MD. “We are very pleased to have Perseus join our investor group during this important growth period for Ascenta.”

    “Ascenta’s strong clinical focus and highly efficient research and development capabilities immediately attracted our attention,” said Perseus’ Selby. “We look forward to working with Ascenta’s Board and management team to create significant value for the company’s investors and employees – and ultimately for patients with cancer.”

    “We welcome Perseus to our Board,” said Eckard Weber, MD, chairman of the Board of Directors of Ascenta. “This new round of funding will advance the company forward during a critical time when the clinical plan for AT-101 is expanding and additional compounds in Ascenta’s innovative pipeline are moving rapidly towards the clinic.”

    Founded in 2003, Ascenta is a privately-held biopharmaceutical company that discovers and develops targeted new medicines for the treatment of cancer. The company has offices in San Diego, California and Malvern, Pennsylvania, and has a preclinical research facility in Shanghai, China. Its technology, licensed from both the National Institutes of Health and the laboratory of Dr. Shaomeng Wang at the University of Michigan, is focused on discovering molecules that hit vulnerable targets in endogenous apoptosis pathways and shut down cell growth and proliferation in cancer cells.

    For more information, please visit www.ascenta.com

Leave a reply

Please leave these two fields as-is:

Protected by Invisible Defender. Showed 403 to 2,458 bad guys.

 

Latest Headlines:

Thursday September 02, 2010
Hub Angels and RRE Ventures Lead $1.9 Million in Series A Funding for Copiun


Tuesday August 31, 2010
VC Firm, Draper Triangle Ventures Invest $5 Million in Series B Funding for ClearCount Medical Solutions


Monday August 30, 2010
PrairieGold Venture Partners Joins Sanderling Venture Partners, vSpring Capital, and Mesa Verde Venture Partners to Add $5 Million to Complete a $10.8 Million Series A Funding Round for Lineagen


Thursday August 26, 2010
Investment Firms, Partech International, El Dorado Ventures, and Sisco Systems Lead $10 Million Investment in Series C Funding for Atlantis Computing


Tuesday August 24, 2010
Mirimar Venture Partners Leads $20 Million in Series C for Brand Affinity Technologies to Promote Celebrity Endorsement and Engagement Business


Monday August 23, 2010
Intersouth Partners Invests $3 Million in 6fusion as Company Relocates to North Carolina


Monday August 16, 2010
ITC Holdings and Kinetic Ventures Lead $18 Million Funding Round In Growth Capital for Cardlytics


Friday August 13, 2010
New Energy Capital Closes $100 Million in First Clean Tech Infrastructure Fund


 

Bad Behavior has blocked 191 access attempts in the last 7 days.